Eli Lilly appoints Mary Lynne Hedley to its Board

Dr. Hedley is an immunologist and cancer cell biologist with considerable pharmaceutical industry experience, particularly within oncology. Since 2021, Dr. Hedley has served as a Senior Scientific Fellow at the Broad Institute of MIT and Harvard. Prior to that, she served as Director, President, and Chief Operating Officer at TESARO, Inc., a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. GlaxoSmithKline plc acquired TESARO in 2019. Prior to founding TESARO, Dr. Hedley was Executive Vice President and Chief Science Officer of Abraxis Bioscience, Inc., where she was responsible for research and development, operations, medical affairs, and business development.

Read also: Eli Lilly, RosVivo Therapeutics ink pact for diabetes treatment

"I am delighted to welcome Dr. Mary Lynne Hedley to the Lilly Board of Directors," said David A. Ricks, chair and chief executive officer. "Mary Lynne has valuable expertise in oncology and the pharmaceutical industry more broadly. Her experience in founding, scaling, and leading biotechnology companies will add tremendous technological and leadership insight to our board."

Dr. Hedley received her Bachelor of Science degree in Microbiology from Purdue University and her Ph.D. in Molecular and Cellular Immunology from UT Southwestern Medical Center. Dr. Hedley completed her postdoctoral training at Harvard University in the areas of immunology and gene regulation.